Back to top
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
J&J Pauses Sales of Atrial Fibrillation Device, Stock Down
Johnson & Johnson’s (JNJ - Free Report) MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to treat atrial fibrillation (AFib) in the United States, as it investigates four reported cases of neurovascular events. The pause on Varipulse procedures began on Jan. 5. The FDA had approved the Varipulse platform in November last year.
The cases were related to an external rollout plan conducted by J&J. Since the beginning of the external rollout till Jan. 3, J&J completed more than 130 cases across 14 sites. The pause does not impact the rollout in outside U.S. markets. Globally, J&J has completed over 3,000 commercial cases of the Varipulse PFA system.
In response to the pause, J&J’s shares slipped around 2.8% on Wednesday.
In the past year, J&J’s shares have declined 12.1% compared with the industry’s 2.9% decrease.
Image Source: Zacks Investment Research
Shares of BSX and MDT Rise
Shares of rivals Boston Scientific (BSX - Free Report) and Medtronic (MDT - Free Report) rose 4.3% and 3.5%, respectively, as these two companies also offer PFA systems in the United States to treat AFib, an abnormal heart rhythm. Medtronic’s PulseSelect PFA device was approved in the United States in December 2023 while Boston Scientific’s Farapulse device was approved in January 2024.
FDA's Fast Track Tag to J&J's Alzheimer's Candidate
In a separate press release, J&J announced that the FDA has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb), for the treatment of early Alzheimer’s disease. The FDA had earlier granted Fast Track status to J&J’s another candidate, JNJ-2056, an anti-tau active immunotherapy for treating preclinical Alzheimer’s disease in July 2024. Both posdinemab and JNJ-2056 are being developed in phase IIb studies.
J&J’s Zacks Rank & Another Stock to Consider
J&J currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Johnson & Johnson Price and Consensus
Johnson & Johnson price-consensus-chart | Johnson & Johnson Quote
Another large drugmaker worth considering is Bristol-Myers (BMY - Free Report) , which has the same Zacks Rank as J&J.
In the past 60 days, estimates for Bristol-Myers’ 2025 earnings have risen from $7.11 per share to $7.19 per share. In the past year, shares of BMY have risen 12.2%.
Bristol-Myers’ earnings beat estimates in each of the trailing four quarters, the average surprise being 15.54%.